HLP005

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.

Interactions

Pharmacology

Pharmacodynamics

HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic. In addition, HLP005 may also inhibit serotonin and dopamine reuptake.

Chemistry

(CYB2108; CYB210010). HLP005 is a phenethylamine derivative and a deuterated compound. The exact chemical structure of HLP005 does not yet seem to have been disclosed. However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated. In addition, HLP005's developer has patent protection for HLP005, indicating that its chemical structure has been published in the patent literature. Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).

Research

HLP005 is under development by Helus Pharma (formerly Cybin). As of November 2025, it is in the preclinical research stage of development for treatment of CNS disorders. The drug was also under development for treatment-resistant psychiatric disorders, but development for this indication was discontinued in November 2025. Other related drugs under development by Helus Pharma include the deuterated tryptamines deupsilocin (HLP003; CYB003) and deudimethyltryptamine (HLP004; CYB004).

See also

Substituted phenethylamine List of investigational hallucinogens and entactogens Deumescaline α,α-Dideuterophenethylamine

References

External links

Development Pipeline – Helus Pharma

Text derived from https://en.wikipedia.org/w/index.php?oldid=1366896965 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.